In a groundbreaking study published in Nature Communications, researchers have unveiled novel genetic variants linked to androgen regulation and hypogonadism that are specific to ancestral backgrounds, utilizing data from the extensive Million Veteran Program. This discovery marks a significant advancement in understanding how genetic diversity influences male reproductive health, opening new avenues for personalized approaches to diagnosing and treating hypogonadism—a condition characterized by abnormally low testosterone levels with widespread clinical consequences.
The Million Veteran Program (MVP), one of the largest and most diverse biobanks in the world, provided an unprecedented dataset integrating genetic, clinical, and ancestral information from hundreds of thousands of men. By leveraging this resource, the team led by Pagadala, Teerlink, and Jasuja conducted a comprehensive genome-wide association study (GWAS) to identify ancestry-specific loci associated with androgen metabolism and hypogonadism phenotypes. Their approach combined high-resolution genotyping with advanced bioinformatic tools, enabling them to parse intricate genetic signals that traditional studies often overlook.
What sets this investigation apart is its focus on ancestry specificity—a crucial consideration often neglected in genetic research. The human genome exhibits considerable variation across populations, shaped by evolutionary history and environmental pressures. These differences can have profound effects on hormone levels and disease susceptibility. Exactly how genetic background shapes androgen-related pathophysiology has remained elusive until now. By stratifying participants according to distinct ancestral lineages, the researchers pinpointed variants that uniquely influence androgen biosynthesis and signaling in certain groups but not others.
Central to androgen biology is the hypothalamic-pituitary-gonadal (HPG) axis, a tightly regulated endocrine feedback system controlling testosterone production. Genetic perturbations at various nodes of this axis can lead to hypogonadism, manifesting in symptoms ranging from reduced libido and muscle mass to infertility and fatigue. Previous genome-wide screens for testosterone-related traits yielded numerous candidates, yet their clinical utility has been hampered by inconsistent replication and lack of functional validation. These newly discovered ancestry-specific genes offer more precise biomarkers with potential causal roles.
Among the most striking findings are variants residing within regulatory regions of genes involved in steroidogenesis, such as those influencing key enzymes converting cholesterol to active androgens. Alterations in enhancer and promoter elements likely modulate gene expression in a tissue-specific manner, especially within Leydig cells of the testes. Additionally, polymorphisms affecting androgen receptor (AR) activity were identified, which impact receptor sensitivity and downstream transcriptional programs crucial for androgenic effects.
The implications of these discoveries extend beyond diagnostic refinement. Clinical management of male hypogonadism could be revolutionized by incorporating genetic risk profiles tailored to ancestral heritage. This precision medicine paradigm promises to optimize hormone replacement therapies, reduce adverse effects, and potentially identify new therapeutic targets by revealing previously unappreciated molecular pathways. For example, individuals of African ancestry carrying specific alleles may benefit from different dosing regimens compared to those of European or Asian descent, minimizing overtreatment or undertreatment scenarios.
Methodologically, the study employed cutting-edge multi-omics integration, combining GWAS signals with epigenomic annotations, transcriptomic data, and proteomic networks. By connecting genotype-phenotype associations with gene expression patterns and protein interactions, the team illuminated the complex biology underpinning androgen regulation. Such holistic analyses are essential to parse the polygenic nature of hypogonadism and to discern direct causal variants from linked markers.
Furthermore, the large sample size and diverse composition of the MVP cohort helped circumvent biases prevalent in previous genetic studies that predominantly sampled individuals of European origin. This inclusivity ensures the findings are more globally applicable and represent a major step toward reducing health disparities. Equally important, the study underscores the scientific imperative of diversity in genetic research, which enhances discovery power and the equitable translation of findings.
Another key aspect addressed is the interplay between genetics and environmental factors influencing androgen levels. Although hypogonadism can be exacerbated by lifestyle, medications, or comorbidities, the discovery of these ancestry-specific genetic determinants suggests intrinsic biological differences contribute substantially. Therefore, future research will need to integrate environmental variables with genetic data to fully characterize individual risk profiles.
Notably, this research also points to potential evolutionary pressures shaping androgen pathways differently across populations. Variants conferring adaptive advantages in certain environments may simultaneously predispose individuals to reproductive health disorders in modern contexts. Understanding this evolutionary dimension could inform public health strategies and highlight the dynamic nature of human genetics.
The findings also raise important questions about the management of hypogonadism in veterans and other populations with disproportionate disease burden. The MVP’s veteran cohort includes individuals exposed to unique stressors, trauma, and environmental hazards that influence endocrine health. Disentangling genetic predisposition from external factors remains a complex but crucial challenge for improving veteran healthcare outcomes.
Future directions outlined by the authors include functional characterization of these ancestry-specific variants through in vitro and in vivo models, as well as clinical trials stratified by genetic background. Such efforts will be vital to translate genomic insights into actionable medical protocols. Moreover, expanding similar analyses to other hormone-related disorders could provide a broader framework for personalized endocrinology.
In sum, this pioneering study exemplifies the power of combining large-scale biobank resources with sophisticated genetic analysis to elucidate complex traits governing human health. The identification of novel ancestry-specific genes for androgens and hypogonadism represents a major milestone that promises to transform research, clinical practice, and ultimately patient outcomes in male reproductive endocrinology. It also highlights the critical importance of diversity and inclusion in biomedical research to address unmet medical needs across populations.
As the medical community continues to grapple with the challenges of hypogonadism diagnosis and treatment, integrating genomics into clinical workflows could soon become standard practice. By tailoring interventions based on an individual’s unique genetic heritage, this work heralds a new era of precise, equitable, and effective healthcare for men worldwide, particularly those historically underrepresented in research.
The unfolding story of ancestry-specific genetic variation and hormone regulation underscores the complexity of biology but also the vast opportunities that modern science offers. Through continued collaboration among geneticists, clinicians, and data scientists, the secrets locked within our DNA will increasingly inform every facet of medicine—ushering in a future where health disparities narrow and each patient receives truly personalized care.
Subject of Research: Genetics of androgen regulation and hypogonadism with a focus on ancestry-specific gene variants.
Article Title: Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
Article References:
Pagadala, M.S., Teerlink, C.C., Jasuja, G.K. et al. Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
Nat Commun 16, 4104 (2025). https://doi.org/10.1038/s41467-025-57372-x
Image Credits: AI Generated
Tags: ancestry and hormone metabolismancestry-specific genetic variantsandrogen regulationbiobanks and genetic researchclinical implications of genetic researchgenetic diversity and health outcomesgenome-wide association study findingshypogonadism researchmale reproductive health geneticsMillion Veteran Program studypersonalized medicine for hypogonadismtestosterone levels and health
